| 摘要 |
The present invention is directed to a pharmaceutical composition comprised of one or more SGLT-2 inhibitor compound (s) in combination with one or more therapeutic agents which is suitable for the treatment of metabolic disorders including type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, postprandial hyperglycemia, overweight, obesity, including class I obesity, class obesity, class III obesity, visceral obesity and abdominal obesity, and metabolic syndrome. |
